Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
REPL 
Replimune Group Inc (REPL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: REPL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.57
1 Year Target Price $12.57
| 3 | Strong Buy |
| 5 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.86% | Avg. Invested days 40 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 761.68M USD | Price to earnings Ratio - | 1Y Target Price 12.57 |
Price to earnings Ratio - | 1Y Target Price 12.57 | ||
Volume (30-day avg) 8 | Beta 0.67 | 52 Weeks Range 2.68 - 14.80 | Updated Date 12/1/2025 |
52 Weeks Range 2.68 - 14.80 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.47 |
Earnings Date
Report Date 2025-11-11 | When Before Market | Estimate -0.84 | Actual -0.9 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -44.83% | Return on Equity (TTM) -96.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 537113340 | Price to Sales(TTM) - |
Enterprise Value 537113340 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.24 | Shares Outstanding 78443334 | Shares Floating 52832370 |
Shares Outstanding 78443334 | Shares Floating 52832370 | ||
Percent Insiders 1.98 | Percent Institutions 106.77 |
Upturn AI SWOT
Replimune Group Inc
Company Overview
History and Background
Replimune Group Inc. was founded in 2015. It focuses on developing oncolytic immunotherapies to treat a range of cancers. It has progressed rapidly from research to clinical trials.
Core Business Areas
- Oncolytic Immunotherapy Development: Replimune focuses on the development of oncolytic viruses designed to selectively replicate in and kill tumor cells while also eliciting a systemic anti-tumor immune response.
Leadership and Structure
Philip Astrow, MD, PhD serves as the Chief Executive Officer. The organizational structure includes research, clinical development, manufacturing, and commercial teams.
Top Products and Market Share
Key Offerings
- RP1: RP1 is Replimune's lead oncolytic immunotherapy candidate being evaluated in multiple clinical trials for various solid tumors. Competitors include companies developing other oncolytic viruses and immunotherapies.
Market Dynamics
Industry Overview
The oncolytic virus therapy market is a growing segment of the oncology therapeutics industry, attracting significant investment and research. It is competitive with many different options available.
Positioning
Replimune is positioned as an innovative leader in the oncolytic immunotherapy space. Its competitive advantage lies in its differentiated platform.
Total Addressable Market (TAM)
The TAM for oncolytic virus therapies is estimated to be billions of dollars. Replimune aims to capture a significant share by developing effective treatments for multiple cancer types.
Upturn SWOT Analysis
Strengths
- Innovative oncolytic immunotherapy platform
- Strong preclinical and clinical data
- Experienced management team
- Strategic partnerships
Weaknesses
- Dependence on successful clinical trial outcomes
- High research and development costs
- Reliance on single lead product candidate
Opportunities
- Expansion into new cancer indications
- Potential for combination therapies
- Strategic collaborations and acquisitions
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immunotherapy approaches
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- AMGN
- MRTX
- BNTX
Competitive Landscape
Replimune competes in the crowded oncology space, differentiating itself with its oncolytic virus platform. It must demonstrate superior efficacy and safety to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Replimune's growth is driven by its clinical development programs and partnerships.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary significantly.
Recent Initiatives: Recent initiatives include advancing RP1 into late-stage clinical trials and expanding its pipeline with new oncolytic virus candidates.
Summary
Replimune is a clinical-stage biotech company with an innovative oncolytic immunotherapy platform. Its success hinges on the positive outcomes of its clinical trials. It faces intense competition and regulatory hurdles. The company has a strong platform but needs to prove its clinical effectiveness to achieve market success. Good news with trials can lead to high returns.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on available information and may be subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Replimune Group Inc
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2018-07-20 | CEO & Director Dr. Sushil Patel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 479 | Website https://www.replimune.com |
Full time employees 479 | Website https://www.replimune.com | ||
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.